Free Testosterone Level Correlated with the Metabolic Abnormalities Dependent on Central Obesity in Women with Polycystic Ovary Syndrome

 

 Buy Article Permissions and Reprints

Abstract

Background:

Women with polycystic ovary syndrome (PCOS) have increased risks of developing metabolic abnormalities compared with the women without PCOS. Hyperandrogenemia is one of the most important characteristics of PCOS. However, the correlations between hyperandrogenemia and metabolic disorders are uncertain.

Aim:

To elucidate the relationship between androgen indices and metabolic abnormalities in Chinese women with PCOS.

Subjects and Methods:

A retrospective analysis of the anthropometric and biochemical records of 408 women with PCOS.

Results:

The prevalence of metabolic syndrome (MetS) was 15.7% in women with PCOS. No association existed between total testosterone (TT) and metabolic profile. Free testosterone (FT) correlated with most of the metabolic variables by unadjusted correlation analyses. The women with elevated FT levels exhibited more unfavorable metabolic profiles compared with the women with normal FT levels. After adjusting for the confounding factors by multivariate logistic regression analysis, the women with elevated FT levels had higher prevalence of central obesity than the women with normal FT levels (odds ratio [OR] 2.346, p=0.042). Women with reduced sex hormone-binding globulin levels were more likely to have central obesity, overweight, raised fasting glucose, insulin resistance, and raised diastolic blood pressure. Raised dehydroepiandrosterone sulfate (DHEAS) level was associated with a lower probability of having central obesity (OR 0.293, p=0.001) and overweight (OR 0.47, p=0.023).

Conclusions:

FT has closer association with metabolic parameters than TT. FT can involve in the development of metabolic disorders dependent on central obesity. Raised DHEAS level can reduce the risks of central obesity and overweight.

• References

• 1 March WA, Moore VM, Willson KJ et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-551
  Google Scholar
• 2 Ni RM, Mo Y, Chen X et al. Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 411-418
  CrossrefPubMedGoogle Scholar
• 3 Cussons AJ, Watts GF, Burke V et al. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008; 23: 2352-2358
  CrossrefPubMedGoogle Scholar
• 4 Moran LJ, Misso ML, Wild RA et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-363
  CrossrefPubMedGoogle Scholar
• 5 Wild RA, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-2049
  CrossrefPubMedGoogle Scholar
• 6 Barber TM, Wass JA, McCarthy MI et al. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66: 513-517
  PubMedGoogle Scholar
• 7 Shroff R, Syrop CH, Davis W et al. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007; 88: 1389-1395
  CrossrefPubMedGoogle Scholar
• 8 Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 2007; 67: 735-742
  CrossrefPubMedGoogle Scholar
• 9 Lindholm A, Andersson L, Eliasson M et al. Prevalence of symptoms associated with polycystic ovary syndrome. Int J Gynaecol Obstet 2008; 102: 39-43
  CrossrefPubMedGoogle Scholar
• 10 Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91: 492-497
  CrossrefPubMedGoogle Scholar
• 11 Fruzzetti F, Perini D, Lazzarini V et al. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril 2009; 92: 626-634
  CrossrefPubMedGoogle Scholar
• 12 Rossi B, Sukalich S, Droz J et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 4780-4786
  CrossrefPubMedGoogle Scholar
• 13 Cagnacci A, Paoletti AM, Arangino S et al. Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. Hum Reprod 1999; 14: 893-897
  CrossrefPubMedGoogle Scholar
• 14 Krotkiewski M, Landin K, Dahlgren E et al. Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS. Gynecol Obstet Invest 2003; 55: 88-95
  CrossrefPubMedGoogle Scholar
• 15 Dahlgren E, Landin K, Krotkiewski M et al. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1998; 13: 2706-2711
  CrossrefPubMedGoogle Scholar
• 16 Elkind-Hirsch KE, Valdes CT, Malinak LR. Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertil Steril 1993; 60: 634-641
  PubMedGoogle Scholar
• 17 Carmina E, Chu MC, Longo RA et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005; 90: 2545-2549
  CrossrefPubMedGoogle Scholar
• 18 Falhammar H, Filipsson H, Holmdahl G et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 110-116
  PubMedGoogle Scholar
• 19 Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480
  CrossrefPubMedGoogle Scholar
• 20 Chen X, Ni R, Mo Y et al. Appropriate BMI levels for PCOS patients in Southern China. Hum Reprod 2010; 25: 1295-1302
  CrossrefPubMedGoogle Scholar
• 21 Standards of medical care in diabetes – 2009. Diabetes Care 2009; 32: S13-S61
  CrossrefPubMedGoogle Scholar
• 22 Chen X, Yang D, Li L et al. Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. Hum Reprod 2006; 21: 2027-2032
  CrossrefPubMedGoogle Scholar
• 23 Kuk JL, Lee S, Heymsfield SB et al. Waist circumference and abdominal adipose tissue distribution: influence of age and sex. Am J Clin Nutr 2005; 81: 1330-1334
  PubMedGoogle Scholar
• 24 Godoy-Matos AF, Vaisman F, Pedrosa AP et al. Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 793-798
  CrossrefPubMedGoogle Scholar
• 25 Despres JP, Moorjani S, Lupien PJ et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511
  CrossrefPubMedGoogle Scholar
• 26 Nestler JE, Powers LP, Matt DW et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89
  CrossrefPubMedGoogle Scholar
• 27 Heald AH, Anderson SG, Ivison F et al. Low sex hormone binding globulin is a potential marker for the metabolic syndrome in different ethnic groups. Exp Clin Endocrinol Diabetes 2005; 113: 522-528
  Article in Thieme ConnectPubMedGoogle Scholar
• 28 Wild RA, Painter PC, Coulson PB et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61: 946-951
  CrossrefPubMedGoogle Scholar
• 29 Chen MJ, Yang WS, Yang JH et al. Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS. Hum Reprod 2006; 21: 2266-2271
  CrossrefPubMedGoogle Scholar
• 30 Selva DM, Hogeveen KN, Innis SM et al. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 2007; 117: 3979-3987
  PubMedGoogle Scholar
• 31 Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974; 3: 69-96
  CrossrefPubMedGoogle Scholar
• 32 Nishizawa H, Shimomura I, Kishida K et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741
  CrossrefPubMedGoogle Scholar
• 33 Luukkaa V, Pesonen U, Huhtaniemi I et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998; 83: 3243-3246
  CrossrefPubMedGoogle Scholar
• 34 Chen MJ, Chen CD, Yang JH et al. High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome. Hum Reprod 2011; 26: 227-234
  CrossrefPubMedGoogle Scholar
• 35 Kauffman RP, Baker VM, DiMarino P et al. Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome. Fertil Steril 2006; 85: 1010-1016
  CrossrefPubMedGoogle Scholar
• 36 Brennan K, Huang A, Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 2009; 91: 1848-1852
  CrossrefPubMedGoogle Scholar
• 37 Carmina E, Lobo RA. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest 2007; 30: 111-116
  PubMedGoogle Scholar
• 38 Marcondes JA, Hayashida SA, Barcellos CR et al. Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. Arq Bras Endocrinol Metabol 2007; 51: 972-979
  CrossrefPubMedGoogle Scholar
• 39 Rittmaster RS, Deshwal N, Lehman L. The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome. J Clin Endocrinol Metab 1993; 76: 1295-1300
  CrossrefPubMedGoogle Scholar
• 40 Jakubowicz DJ, Beer NA, Beer RM et al. Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. J Clin Endocrinol Metab 1995; 80: 3373-3376
  CrossrefPubMedGoogle Scholar
• 41 Wild RA, Umstot ES, Andersen RN et al. Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am J Obstet Gynecol 1983; 146: 602-606
  PubMedGoogle Scholar
• 42 Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab 1996; 81: 59-64
  CrossrefPubMedGoogle Scholar
• 43 Kumar A, Woods KS, Bartolucci AA et al. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2005; 62: 644-649
  CrossrefPubMedGoogle Scholar
• 44 Moran C, Knochenhauer E, Boots LR et al. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril 1999; 71: 671-674
  CrossrefPubMedGoogle Scholar
• 45 Orentreich N, Brind JL, Rizer RL et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59: 551-555
  CrossrefPubMedGoogle Scholar
• 46 Rasmusson AM, Wu R, Paliwal P et al. A decrease in the plasma DHEA to cortisol ratio during smoking abstinence may predict relapse: a preliminary study. Psychopharmacology (Berl) 2006; 186: 473-480
  CrossrefPubMedGoogle Scholar